

THE JOURNAL
OF
MENTAL SCIENCE
(THE BRITISH JOURNAL OF PSYCHIATRY)



BY AUTHORITY OF
THE ROYAL MEDICO-PSYCHOLOGICAL ASSOCIATION

EDITOR-IN-CHIEF
G. W. T. H. FLEMING

WITH THE ASSISTANCE OF
Alexander Walk (Co-Editor)

L. C. Cook	F. L. Golla	T. F. Main
P. K. McCowan	A. Meyer	R. M. Norman
M. Partridge	W. Linford Rees	B. W. Richards
	W. Warren	

(The above constitute the Journal Committee)

AND

Lord Adrian	J. N. P. Moore
W. Ross Ashby	A. A. W. Petrie
Sir F. C. Bartlett	Derek Richter
Sir W. E. le Gros Clark	E. T. O. Slater

VOL. CVI

LONDON
J. & A. CHURCHILL, LTD
MCMLX

PRINTED BY
HEADLEY BROTHERS LTD
THE INVICTA PRESS ASHFORD KENT
AND 109 KINGSWAY
LONDON WC2

For
quick control
of
severe pain

'DOLOXENE'

TRADE MARK

A potent new oral analgesic which, unlike codeine, has practically no constipating effect and does not give rise to nausea. 'Doloxene' is purely an analgesic—it has no antipyretic action, neither does it reduce inflammation. The use of 'Doloxene' in relief of pain in malignant disease will delay the necessity for morphine. No contra-indications or tolerance have been reported.

The average adult dose is 32—65 mg. three or four times daily.

'Pulvules' 'Doloxene' are available in strengths of 32 mg. and 65 mg.

When pain is associated with inflammation or fever

'DOLOXENE COMPOUND'

TRADE MARK

combines the analgesic value of 'Doloxene' with the antipyretic and anti-inflammatory properties of the salicylates. It is highly effective in treating the pain associated with rheumatic diseases, fevers and migraine.

The average adult dose is one or two 'Pulvules' taken three or four times daily.

Each capsule contains :

'Doloxene'	32 mg.
Phenacetin	162 mg.
Acetylsalicylic Acid	227 mg.
Caffeine	32.4 mg.

'Doloxene' brand dextropropoxyphene and 'Doloxene Compound' brand dextropropoxyphene and acetylsalicylic acid compound, are at present subject to the control of the Dangerous Drugs Acts.

Lilly

ELI LILLY AND COMPANY LIMITED
BASINGSTOKE ENGLAND

CONTENTS FOR OCTOBER, 1960

Original Articles—

Some Recent Trends in Neuropathology; by <i>Alfred Meyer</i>	1181
Drug Addiction and Habit Formation; by <i>D. Walton</i>	1195
Conceptual Structure in Thought-Disordered Schizophrenics; by <i>D. Bannister</i>	1230
Purines in the Urine of Normal and Schizophrenic Subjects; by <i>Brenda M. Bollard, R. H. Culpan, N. Marks, H. McIlwain and Michael Shepherd</i>	1250
A Review of Stress Reactivity Research in Relation to Psychopathology and Psychopathic Behaviour Disorders; by <i>J. E. Tong and I. C. Murphy</i>	1273
Families of Dull Children; by <i>Zena Stein and Mervyn Susser</i>	
II. Identifying Family Types and Subcultures	1296
III. Social Selection by Family Type	1304
IV. Increments in Intelligence	1311
On Opening an Adolescent Unit; by <i>G. C. Turle</i>	1320
Urban and Rural Suicide; by <i>Alan Capstick</i>	1327
The Description and Interpretation of Pictures in Cases of Brain Lesion; by <i>G. Ettliger</i>	1337
An Evaluation of Electroplexy (E.C.T.) Techniques; by <i>J. C. Barker and J. G. Thorpe</i>	1347
The Concept of "Dynamic" Consciousness; by <i>R. M. Mowbray</i>	1361
Iodine-132 Uptakes by the Thyroid in Psychotics; by <i>J. L. Crammer and W. F. R. Pover</i>	1371
Problem-Solving Deficits Following Wounds of the Brain; by <i>Hugh Jarvie</i>	1377
Phobia of Outer Space; by <i>R. J. Kerry</i>	1383
The Complexity of Motivations to Suicidal Attempts; by <i>E. Stengel</i>	1388
Psychotic Depression and Age; by <i>G. A. Foulds</i>	1394
Consciousness and the Highest Cerebral Centres, with Remarks on the Penfield-Walsh Controversy; by <i>Max Levin</i>	1398
Endocrine Factors in the Aetiology of Mongolism; by <i>Frederick Edward Kratter</i>	1405
A Controlled Trial of Reserpine in Chronic Schizophrenia; by <i>E. S. Goller</i>	1408
A Comparison Between Prochlorperazine and Chlorpromazine in Mental Deficiency; by <i>H. P. Robb</i>	1413
Phenothiazine Side-Effects: Comparison of Two Major Tranquillizers; by <i>D. M. Somerville, Philip H. Cohen and Gwen. D. Graves</i>	1417
Endogenous Depression Treated with Iproniazid—A Follow-Up Study; by <i>L. G. Kiloh, J. P. Child and G. Latner</i>	1425
Levomepromazine in the Treatment of Neuroleptic Resistant Psychotics; by <i>Peter Payne and David Verinder</i>	1429
A Controlled Trial of Phenelzine in Depressive Reactions; by <i>John A. Harris and A. A. Robin</i>	1432
The Effects of Sodium Amylobarbitone and Dexamphetamine Sulphate on the Peripheral Visual Field; by <i>H. C. Holland</i>	1438
Trial of Imipramine; by <i>Vera Holdway</i>	1443
Imipramine in Chronic Depression; by <i>P. A. Barker, G. W. Ashcroft and J. K. Binns</i>	1447
A Psychometric Assessment of the Effects of Imipramine; by <i>J. E. Orme</i>	1452
Ethinamate and Methypyrone as Hypnotics: A Comparative Trial; by <i>I. C. Lodge Patch, M. D. Eilenberg and E. H. Hare</i>	1455
A Controlled Trial of Haloperidol in Chronic Schizophrenics; by <i>M. D. Enoch and A. A. Robin</i>	1459
Iatrogenic Parkinsonism; by <i>R. H. Boardman and A. G. Fullerton</i>	1468
The Inadequate Psychopath at Camp Hill Prison; by <i>J. S. Knox</i>	1471
Galvanic Skin Response Studies of Sex Responsiveness in Sex Offenders and Others; by <i>J. E. Tong</i>	1475
An Evaluation of the Predictive Power of a Test Known to Differentiate Between Elderly "Functional" and "Organic" Psychiatric Patients; by <i>James Inglis, Catherine Colwell and Felix Post</i>	1486
Dementia: A Clinical and EEG Study of 274 Patients Over the Age of 60; by <i>E. C. Turton and P. K. G. Warren</i>	1493
Tissue Levels of Chlorpromazine in Experimental Animals; by <i>Magdalena Berger Wechsler and Leon Roizin</i>	1501
E.C.T. in Schizophrenia; by <i>A. A. Baker, G. Bird, N. I. Lavin and J. G. Thorpe</i>	1506
Psychological Effects of Stereotaxic Operations for the Relief of Parkinsonian Symptoms; by <i>John McFie</i>	1512
Jung's "Archetypes" and Psychiatry; by <i>Murray Jackson</i>	1518
The Ocular Manifestations of Congenital Toxoplasmosis in Five out of 686 Cases of Mental Deficiency Examined in a State Institution for Mentally Retarded Children, Kingston, North Carolina, U.S.A.; by <i>Frederick Edward Kratter</i>	1527
A Report on the Effects of Phenelzine (Nardil), a Monoamine Oxidase Inhibitor, in Depressed Patients; by <i>R. Middlefell, I. Frost, G. P. Egan and H. Eaton</i>	1533
Psychiatric Illness and Pernicious Anaemia: A Clinical Re-Evaluation; by <i>M. D. Eilenberg</i>	1539
Co-operation in World Mental Health Year; by <i>J. R. Rees, C.B.E.</i>	1549
The Effects of Nicotinic Acid, Nicotinamide, and Placebo on the Chronic Schizophrenic; by <i>W. Ross Ashby, G. H. Collins and Margaret Bassett</i>	1555
The Role of Extra-Sensory Perception in Early Childhood; by <i>Joan Fitzherbert</i>	1560
Sedation Threshold, Personality, and the Theory of Neurosis; by <i>G. S. Claridge and Capt. R. N. Herrington</i>	1568
Severe Reactions to Fentazin in Mental Deficiency Practice; by <i>Peter Sykes</i>	1584

Reviews